This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study.
The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol;
The subject is between 18 and 70 years of age (including borderline values) at the time of signing the ICF, regardless of gender;
The subject has been diagnosed with AS according to the 1984 New York Revised Criteria for Ankylosing Spondylitis
Those who may be allergic to VC005, similar drugs or their excipients.
Individuals who have undergone organ transplantation in the past and require continuous use of immunosuppressants.
Those who, for any reason, are considered by the investigator to be unsuitable for participation in this study.
Parallel
VC005 tablets
DrugVC005 groups repeat administration for 48 weeks
VC005 Tablets Placebo
DrugVC005 placebo groups repeat administration for 48 weeks
Percentage of patients achieving an Assessment of disease activity (signs and symptoms) in ankylosing spondylitis 20% improvement (ASAS20) in response at week 12 of treatment.
Click on the lead sponsor to view all of their trials.
